Antibody Range Expands Drug Monitoring Tools

Bio-Rad Laboratories, extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity). The Company has also launched its first anti-Fc mutation antibody range, targeting drugs containing YTE mutations.

Bio-Rad’s range of highly specific, high-affinity, non-animal derived antibodies are suitable for use in preclinical and clinical pharmacokinetic (PK) and anti-drug antibody (ADA) assays, supporting therapeutic drug monitoring for biologic and biosimilar products. The addition of an antibody specific to dulaglutide marks Bio-Rad’s first antibody against a GLP-1 receptor agonist drug.

The launch of the anti-Fc mutation antibody range now enables the selective detection of YTE-modified therapeutics via the recognition of YTE triple substitutions (M252Y, S254T, and T256E) in the Fc region of human IgG1 antibodies-a modification shown to extend antibody half-life compared to wild-type IgG. The ready-made antibodies are suitable for the development of PK bridging ELISAs to measure free drug concentration in serum.

“With over 350 antibodies of more than 50 different specificities, Bio-Rad’s leading portfolio of monoclonal anti-idiotypic antibodies offers researchers greater flexibility to develop selective, sensitive, and reliable bioanalytical assays,” said Hilary Mavor, Marketing Director, Life Science Group, Bio-Rad Laboratories. “The launch of our first anti-Fc mutation range alongside a new range of anti-biotherapeutic antibodies, including our first against a drug acting as a GLP-1 receptor agonist, marks a significant step beyond classical anti-IDs, underscoring how our technology is adaptable to any new drug format and our commitment to drive innovation across antibody drug discovery.”

This article has been republished from external sources. Note: Material may have been edited for clarity, length, or style. For more information, please contact the cited source.